Inhibitory and fungicidal effects of antifungal drugs against Aspergillus species in the presence of serum

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 4, 2013, Pages 1625-1631

  Elefanti, Antigoni ^a   Mouton, Johan W ^b   Krompa, Katerina ^a   Al Saigh, Rafal ^a   Verweij, Paul E ^b   Zerva, Loukia ^a   Meletiadis, Joseph ^b  

^a UNIVERSITY OF ATHENS   (Greece)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ECHINOCANDIN; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLUS; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS TERREUS; BROTH DILUTION; CONTROLLED STUDY; DRUG MECHANISM; FUNGICIDAL ACTIVITY; FUNGUS GROWTH; FUNGUS ISOLATION; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN BINDING;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; ASPERGILLUS; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; ECHINOCANDINS; HUMANS; MICROBIAL SENSITIVITY TESTS; PYRIMIDINES; SERUM; TRIAZOLES;

EID: 84875160326     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01573-12     Document Type: Article

References (37)

1. Patterson TF, Kirkpatrick WR, White M, Hiemenz JW, Wingard JR, Dupont B, Rinaldi MG, Stevens DA, Graybill Jr. 2000. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine (Baltimore) 79:250 -260.
2. Groll AH, Walsh TJ. 2002. Antifungal chemotherapy: advances and perspectives. Swiss Med. Wkly. 132:303-311.
3. Johnson EM, Oakley KL, Radford SA, Moore CB, Warn P, Warnock DW, Denning DW. 2000. Lack of correlation of in vitro amphotericin B susceptibility testing with outcome in a murine model of Aspergillus infection. J. Antimicrob. Chemother. 45:85-93.
4. Mosquera J, Warn PA, Morrissey J, Moore CB, Gil-Lamaignere C, Denning DW. 2001. Susceptibility testing of Aspergillus flavus: inoculum dependence with itraconazole and lack of correlation between susceptibility to amphotericin B in vitro and outcome in vivo. Antimicrob. Agents Chemother. 45:1456 -1462.
5. Walsh TJ, Petraitis V, Petraitiene R, Field-Ridley A, Sutton D, Ghannoum M, Sein T, Schaufele R, Peter J, Bacher J, Casler H, Armstrong D, Espinel-Ingroff A, Rinaldi MG, Lyman CA. 2003. Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B. J. Infect. Dis. 188:305-319.
6. Warn PA, Sharp A, Denning DW. 2006. In vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug), against Aspergillus spp. J. Antimicrob. Chemother. 57:135-138.
7. Antachopoulos C, Meletiadis J, Sein T, Roilides E, Walsh TJ. 2008. Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia. Antimicrob. Agents Chemother. 52:321-328.
8. Meletiadis J, Antachopoulos C, Stergiopoulou T, Pournaras S, Roilides E, Walsh TJ. 2007. Differential fungicidal activities of amphotericin B and voriconazole against Aspergillus species determined by microbroth methodology. Antimicrob. Agents Chemother. 51:3329 -3337.
9. CLSI. 2008. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard M38-A2, 2nd ed. CLSI, Wayne, PA.
10. EUCAST. 2008. Technical note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia-forming moulds. Clin. Microbiol. Infect. 14:982-984.
11. Baddley JW, Marr KA, Andes DR, Walsh TJ, Kauffman CA, Kontoyiannis DP, Ito JI, Balajee SA, Pappas PG, Moser SA. 2009. Patterns of susceptibility of Aspergillus isolates recovered from patients enrolled in the Transplant-Associated Infection Surveillance Network. J. Clin. Microbiol. 47:3271-3275.
12. Maki K, Matsumoto S, Watabe E, Iguchi Y, Tomishima M, Ohki H, Yamada A, Ikeda F, Tawara S, Mutoh S. 2008. Use of a serum-based antifungal susceptibility assay to predict the in vivo efficacy of novel echinocandin compounds. Microbiol. Immunol. 52:383-391.
13. Zhanel GG, Saunders DG, Hoban DJ, Karlowsky JA. 2001. Influence of human serum on antifungal pharmacodynamics with Candida albicans. Antimicrob. Agents Chemother. 45:2018 -2022.
14. Kauffman CA, Carver PL. 2008. Update on echinocandin antifungals. Semin. Respir. Crit. Care Med. 29:211-219.
15. Zeitlinger MA, Derendorf H, Mouton JW, Cars O, Craig WA, Andes D, Theuretzbacher U. 2011. Protein binding: do we ever learn? Antimicrob. Agents Chemother. 55:3067-3074.
16. Odabasi Z, Paetznick V, Rex JH, Ostrosky-Zeichner L. 2007. Effects of serum on in vitro susceptibility testing of echinocandins. Antimicrob. Agents Chemother. 51:4214-4216.
17. Paderu P, Garcia-Effron G, Balashov S, Delmas G, Park S, Perlin DS. 2007. Serum differentially alters the antifungal properties of echinocandin drugs. Antimicrob. Agents Chemother. 51:2253-2256.
18. Lignell A, Lowdin E, Cars O, Chryssanthou E, Sjolin J. 2011. Posaconazole in human serum: a greater pharmacodynamic effect than predicted by the non-protein-bound serum concentration. Antimicrob. Agents Chemother. 55:3099 -3104.
19. Gifford AH, Klippenstein JR, Moore MM. 2002. Serum stimulates growth of and proteinase secretion by Aspergillus fumigatus. Infect. Immun. 70:19 -26.
20. Rodrigues AG, Araujo R, Pina-Vaz C. 2005. Human albumin promotes germination, hyphal growth and antifungal resistance by Aspergillus fumigatus. Med. Mycol. 43:711-717.
21. Clavaud C, Beauvais A, Barbin L, Munier-Lehmann H, Latge JP. 2012. The composition of the culture medium influences the beta-1,3-glucan metabolism of Aspergillus fumigatus and the antifungal activity of inhibitors of beta-1,3-glucan synthesis. Antimicrob. Agents Chemother. 56: 3428-3431.
22. Antachopoulos C, Meletiadis J, Sein T, Roilides E, Walsh TJ. 2007. Concentration-dependent effects of caspofungin on the metabolic activity of Aspergillus species. Antimicrob. Agents Chemother. 51:881- 887.
23. Meletiadis J, Mouton JW, Meis JF, Bouman BA, Donnelly JP, Verweij PE. 2001. Colorimetric assay for antifungal susceptibility testing of Aspergillus species. J. Clin. Microbiol. 39:3402-3408.
24. Schäfer-Korting M, Korting HC, Rittler W, Obermuller W. 1995. Influence of serum protein binding on the in vitro activity of anti-fungal agents. Infection 23:292-297.
25. Ishikawa J, Maeda T, Matsumura I, Yasumi M, Ujiie H, Masaie H, Nakazawa T, Mochizuki N, Kishino S, Kanakura Y. 2009. Antifungal activity of micafungin in serum. Antimicrob. Agents Chemother. 53: 4559-4562.
26. Paderu P, Park S, Perlin DS. 2004. Caspofungin uptake is mediated by a high-affinity transporter in Candida albicans. Antimicrob. Agents Chemother. 48:3845-3849.
27. Xiong Q, Hassan SA, Wilson WK, Han XY, May GS, Tarrand JJ, Matsuda SP. 2005. Cholesterol import by Aspergillus fumigatus and its influence on antifungal potency of sterol biosynthesis inhibitors. Antimicrob. Agents Chemother. 49:518 -524.
28. Baginski M, Resat H, Borowski E. 2002. Comparative molecular dynamics simulations of amphotericin B-cholesterol/ergosterol membrane channels. Biochim. Biophys. Acta 1567:63-78.
29. Yang YL, Lin YH, Tsao MY, Chen CG, Shih HI, Fan JC, Wang JS, Lo HJ. 2006. Serum repressing efflux pump CDR1 in Candida albicans. BMC Mol. Biol. 7:22.
30. Rajendran R, Mowat E, McCulloch E, Lappin DF, Jones B, Lang S, Majithiya JB, Warn P, Williams C, Ramage G. 2011. Azole resistance of Aspergillus fumigatus biofilms is partly associated with efflux pump activity. Antimicrob. Agents Chemother. 55:2092-2097.
31. Odds FC, Van Gerven F, Espinel-Ingroff A, Bartlett MS, Ghannoum MA, Lancaster MV, Pfaller MA, Rex JH, Rinaldi MG, Walsh TJ. 1998. Evaluation of possible correlations between antifungal susceptibilities of filamentous fungi in vitro and antifungal treatment outcomes in animal infection models. Antimicrob. Agents Chemother. 42:282-288.
32. Andes D, Marchillo K, Stamstad T, Conklin R. 2003. In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model. Antimicrob. Agents Chemother. 47:3165-3169.
33. Mavridou E, Bruggemann RJ, Melchers WJ, Verweij PE, Mouton JW. 2010. Impact of cyp51A mutations on the pharmacokinetic and pharmacodynamic properties of voriconazole in a murine model of disseminated aspergillosis. Antimicrob. Agents Chemother. 54:4758-4764.
34. Lewis RE, Liao G, Hou J, Prince RA, Kontoyiannis DP. 2011. Comparative in vivo dose-dependent activity of caspofungin and anidulafungin against echinocandin-susceptible and -resistant Aspergillus fumigatus. J. Antimicrob. Chemother. 66:1324 -1331.
35. Olson JA, George A, Constable D, Smith P, Proffitt RT, Adler-Moore JP. 2010. Liposomal amphotericin B and echinocandins as monotherapyor sequential or concomitant therapy in murine disseminated and pulmonary Aspergillus fumigatus infections. Antimicrob. Agents Chemother. 54:3884 -3894.
36. Clancy CJ, Nguyen MH. 1998. In vitro efficacy and fungicidal activity of voriconazole against Aspergillus and Fusarium species. Eur. J. Clin. Microbiol. Infect. Dis. 17:573-575.
37. Salas V, Pastor FJ, Calvo E, Alvarez E, Sutton DA, Mayayo E, Fothergill AW, Rinaldi MG, Guarro J. 2012. In vitro and in vivo activities of posaconazole and amphotericin B in a murine invasive infection by Mucor circinelloides: poor efficacy of posaconazole. Antimicrob. Agents Chemother. 56:2246 -2250.